Recruiting
Phase 3

A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Sponsor:

Eli Lilly and Company

Code:

NCT06338995

Conditions

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

LY3650150

Placebo

Standard therapy for INCS

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information